{"title":"作为 KHK 抑制剂治疗非酒精性脂肪肝、NASH 和 II 型糖尿病的新型氰吡啶化合物","authors":"Ram W. Sabnis*, ","doi":"10.1021/acsmedchemlett.4c0033210.1021/acsmedchemlett.4c00332","DOIUrl":null,"url":null,"abstract":"<p >Provided herein are novel cyanopyridine compounds as KHK inhibitors, pharmaceutical compositions, use of such compounds in treating NAFLD, NASH, and type II diabetes, and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 8","pages":"1191–1192 1191–1192"},"PeriodicalIF":4.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes\",\"authors\":\"Ram W. Sabnis*, \",\"doi\":\"10.1021/acsmedchemlett.4c0033210.1021/acsmedchemlett.4c00332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Provided herein are novel cyanopyridine compounds as KHK inhibitors, pharmaceutical compositions, use of such compounds in treating NAFLD, NASH, and type II diabetes, and processes for preparing such compounds.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"15 8\",\"pages\":\"1191–1192 1191–1192\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00332\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00332","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
本文提供了作为 KHK 抑制剂的新型氰基吡啶化合物、药物组合物、此类化合物在治疗非酒精性脂肪肝、NASH 和 II 型糖尿病中的用途以及制备此类化合物的工艺。
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes
Provided herein are novel cyanopyridine compounds as KHK inhibitors, pharmaceutical compositions, use of such compounds in treating NAFLD, NASH, and type II diabetes, and processes for preparing such compounds.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.